WGc‑043: World’s First EBV mRNA Cancer Vaccine Now at Lecheng

When we first read the WHO numbers, we had to put the report down and walk away from our desk. EB virus (Epstein-Barr virus) – that unassuming virus many of us have carried since childhood without even knowing it – is responsible for approximately 250,000 new cancer cases worldwide each year. For decades, patients with EBV-positive cancers such as nasopharyngeal carcinoma and NK/T‑cell lymphoma have faced an agonizing reality: conventional therapies often fail, side effects are debilitating, and when the cancer returns, the options run out.

We cannot tell you how many times we have sat across from those patients, unable to offer anything beyond another round of chemotherapy or palliative radiation. But something happened this month that has fundamentally changed that conversation.

On May 22, 2026, the Boao Lecheng International Medical Tourism Pilot Zone in Hainan became the site of a medical milestone. The world’s first EBV‑related tumor therapeutic mRNA vaccine – WGc‑043 injection – officially entered clinical application at the Hainan Haikong Lecheng Hospital (Sichuan University West China Lecheng Hospital). And for the first time, I find myself able to say to patients: there is hope where there was none before.

Before we explain why this vaccine matters, we need to answer a question our patients ask all the time: if nearly everyone carries EBV, why don’t we all get cancer?

EBV, or Epstein-Barr virus, is a human herpesvirus and the first human tumor virus ever identified. It infects more than 90% of the adult population globally. For most people, the initial infection is either asymptomatic or presents as the common childhood illness we call mononucleosis – fever, sore throat, fatigue – and then, the virus retreats. It goes into latency, hiding quietly inside our B lymphocytes and epithelial cells for the rest of our lives. The vast majority of carriers will never develop EBV-related disease. But for reasons we are still unraveling – involving host genetics, specific viral strains, and environmental triggers – the virus can reactivate and drive malignant transformation.

The World Health Organization’s International Agency for Research on Cancer has classified EBV as a Group 1 carcinogen. It is strongly linked to at least ten malignancies, including nasopharyngeal carcinoma (NPC), Hodgkin’s lymphoma, non‑Hodgkin’s lymphoma, NK/T‑cell lymphoma, gastric cancer, breast cancer, and cervical cancer. In southern China – Guangdong and Guangxi, in particular – the burden is staggering. This region accounts for roughly half of all nasopharyngeal carcinoma cases worldwide. Among Chinese NPC patients, nearly 100% test positive for EBV infection.

For these patients, the options have historically been limited: chemotherapy, radiation, and more recently, immune checkpoint inhibitors. But for those with recurrent or refractory disease – meaning the cancer has returned despite aggressive treatment – the prognosis has been grim. And that is precisely the population that WGc-043 was designed to serve.

WGc-043 is not just another mRNA vaccine. It is the first EBV‑related tumor therapeutic mRNA vaccine in the world to receive Investigational New Drug (IND) approval from both the U.S. Food and Drug Administration and China’s National Medical Products Administration. This is what we call “dual IND approval,” and it matters because it means the vaccine has met rigorous safety and quality standards in two of the world’s most demanding regulatory systems – one Western, one Eastern – simultaneously. Very few mRNA candidates have achieved this, and none before for EBV-associated cancers.

The vaccine emerged from the West China Hospital of Sichuan University, developed by the laboratory of Academician Wei Yuquan (a member of the Chinese Academy of Sciences) and Professor Song Xiangrong, a leading mRNA researcher in China. Their team built the vaccine on WestGene’s proprietary mRNA technology platform, which had already overcome the three core bottlenecks that have long hindered the field: mRNA sequence design, delivery vehicle engineering, and scalable manufacturing.

Technically, what makes WGc-043 special? Let us walk you through it.

First, the antigen selection. The vaccine uses AI‑assisted screening to select the broadest and safest EBV protein sequences – ones that are conserved across different viral strains and capable of triggering a strong, specific immune response.

Second, the immuno‑enhancer. The mRNA molecule incorporates a globally unique, proprietary immuno‑enhancer (IE) that boosts the body’s anti‑tumor immunity. This IE design is original to the WestGene platform and has been patented internationally.

Third, the delivery system. The vaccine is packaged in a novel lipid nanoparticle (LNP) delivery vehicle – WestGene’s own design – that has already been tested for safety in three separate clinical trials. The LNP formulation ensures that the mRNA reaches target cells efficiently without causing the inflammatory side effects that have plagued earlier mRNA platforms.

What does this add up to? When injected, WGc-043 instructs the body’s own cells to produce EBV antigens, which in turn activate the immune system to generate EBV‑specific cytotoxic T cells, antigen‑specific antibodies, and memory T cells. This three‑pronged response allows the vaccine to simultaneously clear the virus itself and kill the tumor cells that the virus helped create. As one researcher put it to us, WGc‑043 effectively achieves what would otherwise require the combination of CAR‑T cell therapy and monoclonal antibodies – but without the astronomical cost, the weeks of ex vivo cell manipulation, or the risk of severe cytokine release syndrome.

As a medical tourism service provider, we live by the evidence. So when we evaluate a new therapy, we ask: what has this actually done for patients?

The data on WGc-043 come from investigator‑initiated trials (IITs) in nasopharyngeal carcinoma and natural killer T‑cell lymphoma – two of the most challenging EBV‑positive cancers to treat. The vaccine has shown superior safety and efficacy compared to existing mRNA cancer vaccines publicly reported to date. In these trials, more than two‑thirds of patients developed EBV antigen‑specific immune responses after treatment. Disease control was outstanding. No Grade 3 or higher toxicities were observed – a safety profile that is exceptional for a cancer therapy.

Compared to traditional cell therapies and targeted drugs, WGc-043 has several practical advantages that matter enormously in real‑world practice. The manufacturing cycle is short; once the mRNA sequence is designed, production can be scaled up rapidly. Administration is as simple as a subcutaneous injection – no IV infusion, no hospitalization, no elaborate preparative regimens. And the safety profile means that even patients who have failed multiple prior treatments can be considered.

For patients who have exhausted all conventional options – those with terminal NPC or NK/T‑cell lymphoma – the arrival of WGc-043 changes the outlook. It does not guarantee a cure, but it offers something that did not exist before: a genuine, scientifically grounded path to immune‑mediated tumor control.

WestGene Biopharma – short for West China‑based Gene therapy – was founded in July 2021 at the Chengdu Tianfu International Bio‑Town. The company’s scientific core comes from the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University. The founding team pairs Academician Wei Yuquan, a veteran cancer researcher and former Chief Scientist of the National 973 Program, with Professor Song Xiangrong, who spent nearly a decade in mRNA research at Harvard Medical School.

In just five years, WestGene has built a pipeline of more than 20 mRNA products spanning oncology, infectious diseases, aging, obesity, and gene editing. The company has not simply imitated existing platforms; it has systematically broken through the core mRNA patents that have long been controlled by Western pharmaceutical giants. WestGene now holds more than 60 invention patents, including 21 international patents. Its ionizable lipid formulation – a key component of the LNP delivery system – has received patent grants in China, the United States, Europe, Canada, Australia, and South Africa.

Beyond WGc-043, WestGene’s HBV‑related tumor therapeutic mRNA vaccine (WGc‑0201) has also received IND approval in both China and the US. The company’s in vivo CAR‑T program has entered clinical trials. Last year, the company completed a 300 million RMB Series A financing round, led by investors including Kangchen Pharmaceutical and Guanghua Wutong. This is not a garage startup. This is a mature biotechnology company with deep academic roots and genuine global ambitions.

And now, thanks to Lecheng’s pioneering “first‑pilot” policies, these innovations are reaching patients years before they would otherwise have been available.

For those who do not follow China’s healthcare reform closely, the Boao Lecheng International Medical Tourism Pilot Zone may sound like just another special economic zone. In practice, it is far more than that. Lecheng is the only national‑level “medical special zone” in China, authorized by the State Council to expedite the import and clinical application of innovative medical devices, drugs, and cell‑based therapies that have not yet received full national approval. It operates on a simple principle: if a therapy is already approved or has strong clinical evidence from a major regulatory authority abroad, and if it addresses a serious clinical need in China, Lecheng can authorize its limited clinical use at designated hospitals.

WGc-043’s arrival at Lecheng is the first time a Chinese‑developed, China‑owned mRNA cancer vaccine has entered clinical application. And it is happening at Hainan Haikong Lecheng Hospital – also known as Sichuan University West China Lecheng Hospital – a facility co‑managed by West China Hospital, one of China’s leading academic medical centers. The hospital has the infrastructure, the regulatory oversight, and the clinical expertise to deliver this therapy safely.

For patients, this means access to a world‑class innovation without the need to travel overseas. For us, in our role at Lecheng, it means we can finally offer a real option to patients who had none.